Neonatal blood (NB) contains substantial numbers of stem and progenitor cells which decline rapidly after birth. Using a combination of cord blood (CB) and NB, we performed a successful, sibling transplant for a thalassaemia patient, leading to the proposal that NB could be used as an adjunct to CB for transplantation. This study was aimed at addressing the feasibility of expanding NB and thus minimizing the volume needed from a NB collection. In the presence of early acting cytokines interleukin-1␤ (IL-1␤), IL-3, IL-6, stem cell factor (SCF), flt-3 ligand with and without thrombopoietin (Tpo), we compared the expansion capacity of CD34 ؉ enriched cells from CB, NB and bone marrow (BM). Flow cytometry and colony-forming unit (CFU) analyses show that Tpo significantly increased the expansion of CD34 ؉ cells from CB and NB to early and committed progenitors. No significant difference was observed between the expansion of CB and NB at 7, 14 or 21 days of culture in terms of CFU, CD34
blood (NB) from his sibling donor. 1 Comparing the CD34 ϩ cell subsets and colony-forming units (CFU) in NB and CB, we demonstrated that stem and progenitor cells were present in substantial quantities in NB. However, their levels declined rapidly after birth. 2 We thus proposed that NB, collected in the first few hours of life, could be used as an adjunct to a marginal volume of CB for transplant. The infusion of the additional stem and progenitor cells from NB might reduce the risk of graft failure and the duration of neutropenia and thrombocytopenia, the latter being known disadvantages of CB transplantation. 3, 4 The safety of the newborn is the major concern of collecting NB. In order to minimize the need for a large volume of NB, one practical approach is the expansion of NB in the presence of cytokines. The ex vivo expansion capacity of CB, BM and cytokine-mobilized peripheral blood (PBSC) has been studied. 5, 6 Although standard protocols of expansion have not been established due to the complexity of cytokine interactions, the use of expanded peripheral blood and bone marrow cells was demonstrated to be feasible and safe in autologous transplants. [7] [8] [9] In our previous study, we successfully expanded NB to the neutrophil and megakarycyte lineages. 2 The present study was carried out to compare the expansion capacity of NB with that of CB and BM, in the presence of early acting cytokines including flt-3 ligand and thrombopoietin (Tpo).
Materials and methods

Blood collection
Peripheral blood samples were obtained from near-term or full-term neonates (gestation age 39.3 Ϯ 0.2 weeks, range 36.4-40.6, weighing 2.5-4.6 kg) during partial exchange transfusion carried out for the treatment of polycythaemia within 12.1 h of life (mean 7.3 Ϯ 1.5 h). These infants had haematocrits ranging from 0.68 to 0.78 (mean 0.72 Ϯ 0.14) before exchange transfusion. Partial exchange transfusion was performed with an indwelling umbilical venous or radial arterial catheter for blood withdrawal, and a peripheral venous catheter for simultaneous replacement with isotonic saline. Cord blood was collected from normal deliveries of similar gestation age (mean 39.3 Ϯ 1.4 weeks, range 37.0-41.2). Bone marrow samples were obtained from normal marrow transplant donors. Blood and marrow samples were collected in sterile tubes containing preservative-free heparin (10 IU/ml, David Bull Laboratories, Victoria, Australia). All except seven samples were processed fresh and laboratory analyses were carried out immediately. One NB and three CB samples were cryopreserved and three NB samples were stored overnight at 4°C before CD34 ϩ selection. The study was approved by the Ethics Committee for Clinical Research of The Chinese University of Hong Kong. Parental or patient consents were obtained before all blood collections.
Ex vivo expansion protocol
Mononuclear cells (MNC) from NB, CB and BM were obtained by Ficoll-Paque separation (1.077 g/ml, Pharmacia, USA). CD34 ϩ cells were enriched using immuno-magnetic selection as recommended by the manufacturer (MiniMacs; Miltenyi Biotec, Gladbach, Germany). The purity of CD34 ϩ cells from the selection of CB, NB and BM was 82.5 Ϯ 2.3%, 75.9 Ϯ 5.4% and 87.9 Ϯ 2.8%, respectively. Enriched CD34 ϩ cells were cultured at 1 ϫ 10 4 cells per ml in Iscove's modified Dulbecco's medium (IMDM; Gibco, NY, USA) and supplemented with 20% fetal calf serum (FCS; Gibco). Human recombinant cytokines 10 ng SCF, 3 ng IL-1␤, 100 ng IL-3, 100 ng IL-6, 50 ng Tpo and 100 ng flt-3 ligand per ml were included in the cultures. Optimal concentrations of Tpo and flt-3 ligand were determined by pilot studies on CB samples. All cytokines were products of Genzyme, Boston, MA, USA. The enriched CD34 ϩ cells (4 ml in volume) were incubated in 25-cm 2 vented culture flasks (Corning, Acton, USA) at 37°C and 5% CO 2 for 21 days. The culture was demi-depopulated at day 7 and day 14 during which fresh medium and cytokines were added. Cell counts, viability count by trypan blue exclusion, stem cell and lineage marker expression, immunocytochemistry and colonyforming units (CFU) were analysed.
Flow cytometry and monoclonal antibodies
CD34
ϩ cell subsets and other cell surface markers were measured by three-colour flow cytometry. The lysed whole blood method, using the FACS lysing solution, was performed according to the protocol of Becton Dickinson (BD), San Jose, CA, USA. Ten thousand events were acquired using LysisII software. Nucleated cell counts were determined by a haemacytometer. The following fluorescent-conjugated monoclonal antibodies were products of BD: CD34-fluorescein isothiocyanate (FITC), CD38-phycoerythrin (PE), CD33-PE, HLA-DR-peridinin chlorophyll protein (PerCP), CD3-FITC, CD3-PerCP, CD4-FITC, CD8-PE, CD16-PE, CD56-PE and isotypic control-PerCP. CD45-FITC, CD14-PE, CD61-FITC, CD41-PE, CD19-FITC and control-FITC/PE were manufactured by Dako, Copenhagen, Denmark. CD71-FITC was a product of Immunotech, Marseille, France.
Colony-forming units
Enriched CD34
ϩ cells and expanded cells from NB, CB and BM at 3 ϫ 10 3 per ml were cultured on 3% methylcellulose (Sigma Chemical, St Louis, MO, USA) in IMDM and supplemented with 30% FCS, 1% bovine serum albumin (Sigma), 100 m ␤-mercaptoethanol, 100 U/ml penicillin and 50 mg/ml streptomycin. The assay of CFU included colony-forming unit granulocyte-macrophage (CFU-GM), colony-forming unit erythroid (CFU-E), burstforming unit erythroid (BFU-E) and colony-forming unit granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM). Granulocyte-macrophage colony-stimulating factor (GM-CSF, R; Sandoz, Basle, Switzerland) at 100 ng/ml, SCF at 20 ng/ml, erythropoietin (Epo; Eprex, Zug, Switzerland) at 1 IU/ml were included in the medium. All CFU cultures were performed in triplicate, maintained at a fully humidified atmosphere at 37°C with 5% CO 2 and scored after 14 days. Colonies of more than 50 cells were counted.
For megakaryocyte (MK) progenitor (CFU-MK) assays, 20 ng Tpo (without other growth factors) was added to cultures in methylcellose. CFU-MK were identified using an immunocytochemical method and anti-CD41 antibody (Dako) as previously described. 10 A CFU-MK colony is defined as a cluster of three or more MK cells.
Morphology and immunocytochemical staining
Cultured cells were washed and incubated with FITC and PE-labelled antibodies at 4°C for 20 min in the dark. These cells were washed, suspended in 20% FCS in IMDM and cytospun on to slides. They were then fixed with absolute methanol for 2 min, stored under a mounting buffer at 4°C and examined under a fluorescence microscope.
Statistical analysis
We used the analysis of variance to compare cell numbers and subsets of NB, CB and BM. The paired t-test was used to study the effects of Tpo treatment on these samples. A P value of less than 0.05 was considered to be statistically significant. All results were expressed as mean Ϯ 1 standard error of mean (s.e.m.).
Results
Effects of Tpo on ex vivo culture
Seven CB, four NB and three BM samples were expanded in the presence of IL-1␤, IL-3, IL-6, flt-3 ligand, SCF with and without Tpo. Results indicated that Tpo increased the expansion capacity of CD34 ϩ enriched cells in general. This was especially significant in cultures of CB and NB at day 7 ( Figure 1 ) and day 14, whilst the effects were not so apparent at day 21. Tpo significantly increased the following parameters (P Ͻ 0.05): (1) levels were significantly increased with the addition of the cytokine. In view of the positive effects of Tpo on the expansion of early and committed progenitors from NB and CB, further comparisons were performed with the addition of Tpo.
Comparison of CB, NB and BM expansion
CD34
ϩ cells from eight CB, 10 NB and four BM samples were enriched using immunomagentic beads. The starting CD34 ϩ enriched cells (day 0) in these sources contained similar levels of CFU-GM, CFU-MK and CD34 ϩ cells but BM had significantly fewer CD34 ϩ CD38 Ϫ early progenitors (P Ͻ 0.05) when compared with those of CB or NB (1502 Ϯ 614 cells/ml in CB, 942 Ϯ 152 cells in NB and 38.8 Ϯ 6.57 cells in BM).
All samples were expanded in terms of the number of total nucleated cells, CD34 ϩ , CD34 ϩ CD38 Ϫ , CFU-GM and CFU-MK (Figure 2 ). The total nucleated cells (NC) increased with the duration of culture. CD34 ϩ progenitor subsets and colonies generally declined after 14 days. The expansion capacity of CD34 ϩ enriched cells from BM was significantly lower than that of NB and CB. No significant difference was observed between the expansion of CB and NB at days 7, 14 or 21 except that at day 21, CB contained more nucleated cells (P Ͻ 0.05). With the present expansion and CFU culture conditions, the major CFU were CFU-GM with very few CFU-GEMM (not reported). Progenitors of the erythroid lineage, BFU-E and CFU-E were detected in most of the day 7 cultures (17.3 Ϯ 11.4-fold in CB; 80.0 Ϯ 37.6-fold in NB; 26.6 Ϯ 26-fold in BM) but not in day 14 (except one NB sample) or day 21 cultures.
Although the overall cell number increased after expansion, the proportion of CD61 ϩ CD41 ϩ cells decreased with the duration of culture. Their levels were as follows: (1) CB: 2.74 Ϯ 0.55% of NC at day 7, 2.35 Ϯ 0.34% at day 14, 1.78 Ϯ 0.68% at day 21 (P Ͻ 0.05); (2) In contrast was the percentage of HLA-DR ϩ cells which were not different in the three sources or Tpo treatments but appeared to decrease with culture duration from over 50% in day 7 to below 20% at day 21 (P = 0.054 for NB culture).
Another observation was that at day 7, the expansion of NB was highest among the three groups (Figure 2 ). This was not only due to the high level of nucleated cells. The percentage of CD34 ϩ cells in NB (8.69 Ϯ 1.16%) was also significantly higher than that in CB (5.47 Ϯ 0.87%) and BM (2.68 Ϯ 0.42%). In contrast, levels of these subsets at day 14 were generally highest in CB when compared to those in NB and BM (except CFU-GM). CFU-GM levels appeared consistently high in the NB group, although significant differences (P Ͻ 0.05) was only observed between NB and BM at days 7, 14 and 21.
Immunophenotyping of expanded cells
Flow cytometry analysis showed that the expanded cells from CB, NB and BM were mostly of the myeloid lineage with over 80% being CD45 ϩ CD33 ϩ cells. We did not detect CD3 ϩ , CD19 ϩ , CD16 ϩ CD56 ϩ cells in the expansion. Morphological and immunocytochemical studies showed heterogeneous populations of progenitors ( Figure  3) . The cell viability in day 7 and day 14 cultures was over 95%, but increased cell death was observed at day 21, possibly due to high cell density.
Discussion
Using various protocols of expanding CD34 ϩ enriched cells, previous workers have reported favourable engraftment outcomes in autologous transplantation. [7] [8] [9] In our expansion procedure, we used cytokines such as SCF, flt-3 ligand, IL-1␤, IL-3 and IL-6 which are known promoters of early progenitors. 5, 6, 11 In addition, we included Tpo, which was reported to be the most effective growth factor of the megakaryocyte lineage 12 and an activator of early progenitor expansion. 13, 14 The Tpo receptor, mpl, was observed in CD34 ϩ cells and the megakaryocyte lineage. 15, 16 Our results demonstrated that after treatments with Tpo, the expansion capacity of CD34 ϩ cells from CB, NB and BM was significantly enhanced, resulting in the greater production of early progenitors (CD34 ϩ CD38
Ϫ cells) and CFU of the granulocyte-macrophage and megakaryocyte lineage.
Using our expansion protocol, we observed that the expansion capacity of BM to progenitor cells and colonies was significantly lower than that of CB or NB. This could be due to the low initial proportion of CD34 ϩ CD38 Ϫ early progenitor cells in the BM samples. The superior expansion capacity of CB over BM has been suggested. [17] [18] [19] Our study 
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؉ cells from neonatal blood J Liu et al demonstrated for the first time that NB had an expansion capacity similar to CB in most aspects. Because of the variation in experimental conditions, particularly in the combination and concentration of cytokines used, our study was not intended to compare the expansion capacity of our cell sources with those previously reported. Nevertheless, the expansion of CD34 ϩ cells, CFU-GM and CFU-MK by over 11-, 298-and 127-fold, respectively, after 7 days in NB cultures represents an effective expansion outcome.
An interesting observation is the relatively rapid expansion of NB, which was apparent at day 7, at which time the expansion of CB and BM remained low. One possible explanation is the presence of a rapid proliferation and/or differentiation process of stem and progenitor cells in the immediate postnatal period. We have previously shown that the level of CD34 ϩ cells was reduced by over 30% in the peripheral blood within 4 h after birth. 2 Although the regulation of haematopoietic cell differentiation at the first few hours of life is at present not clear, this observation indicated that there is an active regulatory mechanism of haematopoietic development in the newborn, possibly induced by parturition. The efficient expansion of NB suggested an advantage over other sources of stem cells. A relatively short culture duration such as 7 to 10 days with one addition of medium and cytokines could be sufficient for the provision of early myeloid and megakaryocytic progenitors.
The ethics and practicality of using NB as an adjunct to a collection of CB for transplantation very much depends on the volume of NB that needs to be removed from the donor neonate. The present study demonstrated the feasibility of expanding NB, thus providing a possible means for reducing the amount of donor blood required. Although CB has been shown to possess a high expansion capacity, 13 there is no clinical evidence showing that the infusion of expanded CB cells contribute to long-term engraftment. The strategy of using expanded NB in combination with unmanipulated CB for transplantation satisfies the need for infusing more progenitor cells and preserving the high quality pluripotent stem cells of CB.
